IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07483567 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

CLDN18.2 Positive
Primary Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: IBI343,sintilimab,oxaliplatin,S-1
DRUG: sintilimab,oxaliplatin,S-1

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.